Turn Therapeutics Details Strong Phase 2 Atopic Dermatitis Results and Pipeline Strategy in Investor Presentation
TTRX has more than doubled off its 52-week low of $2.57 on elevated volume (2.2× avg).
Summary
Turn Therapeutics released an investor presentation with detailed positive interim Phase 2 data for its lead drug GX-03 in Atopic Dermatitis, alongside updates on its Onychomycosis program and financial runway.
Key Events · Product Development and Regulatory · TTRX
-
Strong Interim Phase 2 AD Data Detailed
Detailed results for GX-03 in Atopic Dermatitis showed a 79.43% mean EASI reduction at Week 4 and a 77.22% reduction at Week 8, alongside significant IGA improvements and a favorable safety profile.
-
Trial Optimization for GX-03 AD
The company plans to emphasize Week 4 endpoints, particularly EASI-75, for Stage 2 of the Phase 2 trial and is preparing for a Type B meeting with the FDA to optimize the development pathway.
-
GX-03 for Onychomycosis is Phase 3 Ready
The presentation highlights GX-03's readiness for Phase 3 in toenail fungus, supported by prior studies showing 70-85% efficacy and no adverse events.
-
Cash Runway into Q1 2027 Confirmed
The company reported $11 million in cash as of March 31, 2026, extending its financial runway into the first quarter of 2027, with additional financing options available.
Analysis · TTRX · Life Sciences
This 8-K furnishes an updated investor presentation detailing the strong interim Phase 2 clinical trial results for GX-03 in moderate to severe Atopic Dermatitis, which were initially announced on June 1st. The presentation provides granular efficacy data, including significant EASI and IGA improvements, and outlines the trial optimization strategy for Stage 2. It also highlights the Phase 3 readiness of GX-03 for Onychomycosis and reiterates the company's cash runway into Q1 2027, providing crucial context for its financial stability following previous going concern disclosures.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.9% of the 1009 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TTRX was trading at $6.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $191.2M. The 52-week trading range was $2.57 to $26.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.